首页|期刊导航|中华医学杂志：英文版|Application of proprotein convertase subtilisin/kexin type 9 inhibitor, evolocumab, in patients with severe hypertriglyceridemia

Application of proprotein convertase subtilisin/kexin type 9 inhibitor, evolocumab, in patients with severe hypertriglyceridemiaOACSCDCSTPCDMEDLINESCI

中文摘要

To the Editor:The proprotein convertase subtilisin/kexin type 9(PCSK9)-inhibitor,evolocumab,can bind with PCSK9 in plasma and reduce the degradation of the PCSK9-low density lipoprotein(LDL)receptor complex,thereby reducing L…查看全部>>

作者：Yanren Peng;Danxia Guo;Sijie Jiang;Hua Zheng

作者单位：Department of Cardiology,Nanfang Hospital,Southern Medical University,Guangzhou,Guangdong 510515,ChinaDepartment of Cardiology,Nanfang Hospital,Southern Medical University,Guangzhou,Guangdong 510515,ChinaDepartment of Cardiology,Nanfang Hospital,Southern Medical University,Guangzhou,Guangdong 510515,ChinaDepartment of Cardiology,Nanfang Hospital,Southern Medical University,Guangzhou,Guangdong 510515,China

分类：临床医学

中文关键词：patientslipoproteinconvert

刊名：《中华医学杂志：英文版》 2022 (6)

页码/页数：P.730-731,2

DOI：10.1097/CM9.0000000000001896

您当前未登录！

去登录

点击加载更多...

Application of proprotein convertase subtilisin/kexin type 9 inhibitor, evolocumab, in patients with severe hypertriglyceridemiaOACSCDCSTPCDMEDLINESCI

评论